Inactivated Polio and Rabies Vaccines Market Report 2025

The inactivated polio and rabies vaccines market size has grown strongly in recent years. It will grow from $2.16 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increasing vaccination campaigns, rising awareness about polio and rabies, government immunization programs, high incidence rates of polio and rabies in certain regions, and support from international health organizations.

The inactivated polio and rabies vaccines market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to advancements in vaccine technology, growing demand for vaccination in emerging markets, increased focus on global health security, government policies promoting vaccination, rising healthcare expenditure on preventive measures, etc. Major trends in the forecast period include increasing demand for combined polio and rabies vaccines, advancements in freeze-drying technology for vaccine stability, development of single-dose formulations for easier administration, advancements in cold chain logistics for improved vaccine distribution, growth in global immunization programs, and government-funded vaccination initiatives.

The forecast of 5.5% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Import restrictions could challenge vaccination programs by increasing prices of combination inactivated viral vaccines manufactured in the Netherlands and South Korea, potentially reducing immunization coverage and raising public health costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing demand for effective vaccination programs is expected to drive the growth of the inactivated polio and rabies vaccines market. Vaccination programs, organized by governments or organizations to protect people from diseases, are becoming more widespread as governments intensify efforts to prevent outbreaks, reduce healthcare costs, and improve public health. These initiatives contribute to the demand for inactivated polio and rabies vaccines by raising awareness, securing funding, and expanding coverage in high-risk areas. Mass vaccination campaigns and routine immunizations, often led by governments and health organizations, ensure consistent vaccine uptake. For example, in April 2024, the Pan American Health Organization (PAHO) reported that the 22nd Vaccination Week in the Americas (VWA), themed Engage now to protect your future, GetVax, aimed to boost vaccination coverage in underserved areas by administering over 65 million doses. The initiative also worked to combat misinformation and improve vaccine access through community engagement and tailored campaigns. This growing demand for effective vaccination programs is driving the growth of the inactivated polio and rabies vaccines market.

Companies in the inactivated polio and rabies vaccines market are advancing product development, such as inactivated rabies vaccines, to improve immunogenicity and address the global demand for effective disease prevention. Killed virus rabies vaccines are made using a rabies virus that has been rendered non-infectious through chemical or physical processes. These vaccines stimulate the immune system to produce protective antibodies without causing the disease, making them safe and effective for both pre- and post-exposure use. For example, in April 2024, Sanofi, a UK-based pharmaceutical company, launched Verorab, an inactivated rabies vaccine, in the UK for both pre-exposure and post-exposure prophylaxis of rabies for all age groups. The vaccine, approved in the UK based on extensive clinical data from over 13,000 individuals, has been widely used in over 80 countries. Verorab offers an effective immunization option for travelers to high-risk countries and for rabies post-exposure treatment, with clinical trials showing strong immune responses and long-lasting protection.

In June 2024, Sanofi partnered with Biovac, a South Africa-based biopharmaceutical company, to support local vaccine production in Africa. This collaboration aims to establish sustainable local manufacturing of inactivated polio vaccines (IPV), enhancing regional self-sufficiency and advancing polio eradication efforts across more than 40 African countries. Biovac specializes in developing vaccines for diseases that disproportionately affect people in Africa.

Major players in the inactivated polio and rabies vaccines market are Merck & Co Inc., Sanofi S.A., LG Chem Ltd., Boehringer Ingelheim International GmbH, Sinovac Biotech, Zoetis Inc., Cadila Pharmaceuticals, Zydus Lifesciences Limited, Biological E. Limited, Serum Institute of India (SII), Indian Immunologicals Limited (IIL), Instituto Butantan, Valneva SE, Bio Farma, Bharat Biotech, Bilthoven Biologicals, Panacea Biotec, Batavia Biosciences, Hilleman Laboratories, and China National Pharmaceutical Group Co Ltd.

North America was the largest region in the inactivated polio and rabies vaccines market in 2024. The regions covered in inactivated polio and rabies vaccines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the inactivated polio and rabies vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inactivated polio and rabies vaccines market consists of sales of combination vaccines containing inactivated polio vaccine (IPV), pre-exposure prophylaxis vaccines, and post-exposure prophylaxis (PEP) kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold to the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The inactivated polio and rabies vaccines market research report is one of a series of new reports that provides inactivated polio and rabies vaccines market statistics, including the inactivated polio and rabies vaccines industry global market size, regional shares, competitors with the inactivated polio and rabies vaccines market share, detailed inactivated polio and rabies vaccines market segments, market trends, opportunities, and any further data you may need to thrive in the inactivated polio and rabies vaccines industry. This inactivated polio and rabies vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Inactivated polio and rabies vaccines (IPV) are designed to protect individuals from polio and rabies, respectively. Both vaccines are made using viruses that have been inactivated, meaning they cannot cause disease. IPV prevents poliomyelitis, a viral illness that can lead to paralysis, while the inactivated rabies vaccine offers protection against rabies, a fatal infection usually transmitted through animal bites. These vaccines stimulate the immune system to provide long-lasting protection without causing illness.

The primary product types of inactivated polio and rabies vaccines include the inactivated polio vaccine and inactivated rabies vaccine. The inactivated polio vaccine (IPV) is a safe, injectable vaccine derived from inactivated poliovirus, designed to strengthen immunity and protect against polio without causing infection. It is inactivated using various methods, such as the solvent-detergent method, radiation, pH concentration, heat inactivation, and others. The vaccine is distributed through several channels, including both government and private sectors, for use in different populations, such as pediatrics and adults.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.